Leveraging a Humanized SLE Mouse Model to Evaluate Next-Generation Immune-Cell-Targeted Therapeutics (Download)
Facebook LinkedIn Fill out the form below to download this content.
Integrated Mass Spectrometric Workflows Enabling Next-Generation Conjugate Therapeutics in Cancer Research (Download)
Facebook LinkedIn Fill out the form below to download this content.
From Sequence Design to AOC Production Medicilon’ s End-to-End RNAi Development Platform (Download)
Facebook LinkedIn Fill out the form below to download this content.
ASMS 2026
May 31 – June 4, 2026
San Diego Convention Center
Developing PDX-Derived Organoid Models for Efficacy Evaluation of Anticancer Therapies (Download)
Facebook LinkedIn Fill out the form below to download this content.
KSNS 2026
May 29, 2026
Suwon Convention Center
Nordic PMF 2026
May 11-12, 2026
Elite Hotel Marina Tower, Stockholm, Sweden
AACR 2026 Special Report: An In-Depth Review of Medicilon’s Three Technical Posters | Bilingual
The AACR Annual Meeting convenes leading cancer experts in San Diego, California, from April 17-22, 2026. Medicilon, with over 20 years of preclinical CRO experience, is represented by Dr. Qingcong Lin, Dr. Mingfeng Bai, and Dr. Steven Zhang. The team is presenting three technical posters highlighting Medicilon’s integrated solutions in conjugate drug analysis, autoimmune CAR-T evaluation models, and end-to-end AOC/RNAi drug […]
ICDD 2026
April 22–23, 2026
Budapest, Hungary
Medicilon Signs Five-Year Strategic Cooperation Agreement with BioPartners X to Jointly Promote Innovative Drug R&D
On March 31, 2026, Medicilon officially signed a long-term strategic cooperation framework agreement with BioPartners X. Mr. Gong Huimin, Chairman and CEO of BioPartners X, Dr. Liu Tong, Chief Scientist, Mr. Luo Wusong and Mr. Xu Changlu, Vice Presidents of Strategic Investment, and Mr. Li Ao, Non-Clinical Director, together with Dr. Chen Chunlin, Founder and […]
